Catalyst SDMA Test innovations improve workflow and decrease time to get results

Symmetric dimethylarginine (SDMA) is a methylated form of arginine present in the intracellular proteins of nucleated cells in vertebrates. SDMA is excreted through the kidneys and correlates well with the glomerular filtration rate (GFR) in people, dogs, and cats.^{1–4}

The IDEXX Catalyst[®] SDMA Test, which can be run on the Catalyst One[®] and Catalyst Dx[®] chemistry analyzers, has been commercially available since 2017. As an indirect marker of GFR, it complements other biomarkers of kidney function such as creatinine and BUN. SDMA is a sensitive indicator of kidney function that detects, on average, a loss of 40% in kidney function, often detecting damage that remains undetected by other parameters.¹⁻⁴ Creatinine typically does not exceed the reference cutoff until GFR is reduced by 75%.^{1,4,5}

SDMA increases with the occurrence of both acute or active kidney injury and chronic kidney disease, allowing veterinarians to intervene earlier for more successful outcomes. Furthermore, SDMA, unlike creatinine, is often not impacted by lean body mass.^{1,2,46,7} For these reasons, the Catalyst SDMA Test is an essential parameter on all routine chemistry profiles, allowing for a thorough assessment of kidney function.

The new Catalyst SDMA Test innovations

Innovations to the new Catalyst SDMA Test have improved workflow and have decreased the time it takes to get results, while continuing to provide exceptional performance. This new slide can be stored along with current biochemistry slides in the freezer, can be run in any order with other Catalyst slides or CLIPs, and no longer requires the reagent cup.

The new slide design is still compatible with serum and lithium heparin plasma from dogs or cats without the need for dilution. The new Catalyst SDMA Test will be available for both the Catalyst One and the Catalyst Dx chemistry analyzers. It has the same reference interval $(0-14 \mu g/dL)$, interpretive guidelines, and reportable range $(0-100 \mu g/dL)$ as the reference laboratory IDEXX SDMA® Test. The new Catalyst

Compatibility	Workflow
 + Can be stored in the freezer with other Catalyst[®] slides + Optimized for Catalyst Dx and Catalyst One analyzers 	 + Reagent cup removed + Can be run in any order with other Catalyst slides + Faster result times

SDMA Test provides an accurate assessment of kidney function with improved workflow and efficiency.

The new Catalyst SDMA Test is the result of IDEXX's investment in innovation to improve workflow and practice efficiency, decrease plastic waste, and optimize performance using the best-in-class technology. The new Catalyst SDMA Test is a streamlined product developed with IDEXX SmartService[™] in mind to allow for hands-free upgrades and for management to ensure continued reliability.

Description of study (methods)

Comparing the new Catalyst SDMA Test with the gold-standard reference method liquid chromatography mass spectrometry (LC-MS) SDMA was conducted according to Clinical Laboratory Standards Institute (CLSI) guidelines.^a A total of 192 serum or plasma samples were collected from 46 cats and 146 dogs for evaluation. All samples were collected at the discretion of the veterinarian for diagnostic purposes. Samples were analyzed on the new Catalyst SDMA Test slide within hours of sample collection, either on the Catalyst Dx analyzer (73 samples) or the Catalyst One analyzer (119 samples); then the samples were shipped to IDEXX R&D (Westbrook, Maine) and frozen at -80°C until they underwent an analysis by LC-MS within 90 days. LC-MS samples were measured in duplicates and reported as the mean result. Only fresh samples were used for the new Catalyst SDMA Test, since stored and frozen samples are not appropriate for the Catalyst SDMA Test. Outliers were screened using the Tukey fences method; no outliers were detected.

Precision was assessed using recombinant SDMA-spiked samples with concentrations of $13-15 \mu g/dL$ and $55-60 \mu g/dL$. Samples were analyzed 6 times per day over 5 days on instruments (12 Catalyst One and 12 Catalyst Dx analyzers).

The potential for interference from hemolysis, lipemia, and icterus was evaluated in spiked canine plasma with SDMA concentrations of $10-15 \mu g/dL$, $25-30 \mu g/dL$, and $55-60 \mu g/dL$. Spiked samples were used to mimic 5 interferent concentrations ranging from 0-500 m g/dL for hemolysis and lipemia, and 0-40 m g/dL for icterus.

Results and discussion

Method comparison of the Catalyst SDMA Test and LC-MS SDMA

SDMA values from the new Catalyst[®] SDMA Test were strongly correlated with SDMA values from the gold standard, LC-MS SDMA (figure 1).^{1.4} Only fresh clinical serum samples were analyzed with the new Catalyst SDMA Test, as this technology is optimized for fresh, unrefrigerated samples run preferably within 2 hours of drawing blood. The use of stored or frozen samples could have impacted clinical interpretation and would have been inappropriate for performance evaluation. None of the clinical samples had SDMA concentrations at the upper extreme of the analytical range, but the samples were distributed across the clinically relevant range. Therefore, the regression plot provides valuable information about the expected performance on clinical samples.



Figure 1: Scatter plot with least squares best fit line showing relationship of results from the new Catalyst SDMA Test to results from the gold-standard LC-MS SDMA. Results for 192 canine and feline samples are shown.

Precision

The precision determined for the new Catalyst SDMA Test across both the Catalyst One® and Catalyst Dx® analyzers, as well as the different test days (table 1), is consistent with the previously reported precision for the reference laboratory IDEXX SDMA Test and LC-MS SDMA.

Replicates	Mean concentration (µg/dL)	Standard deviation (µg/dL)	CV%
720	16.12	1.49	9.27
720	60.93	2.37	3.89

Table 1: Summary of precision analysis for the new Catalyst SDMA Test across 12 Catalyst One and 12 Catalyst Dx analyzers

 and 5 days at one concentration close to the reference interval and one at the upper end of the detectable range.

No clinically significant interference was seen with any level of hemolysis, lipemia, or icterus at any of the tested SDMA concentrations.

Clinical use and benefit of the new Catalyst SDMA Test in real-time care

As a component of the chemistry panel, SDMA adds substantial value for both sick and well patients in the early detection of primary kidney diseases and secondary functional decline due to concurrent disease. Since SDMA is a sensitive, reliable, early indicator of GFR impairment, its increase will often be the first indication of decline in kidney function.^{1–4,10} These key features of SDMA allow for diagnosis and early management of otherwise undetectable kidney disease and can contribute to the recognition of undiagnosed concurrent diseases.

The use of SDMA in real-time care settings is especially informative for pre-anesthetic and sick patient assessments. A single increase in SDMA can be a medical turning point and the first indication of decline in GFR and kidney disease.^{10,11} A thorough assessment of kidney function can allow for earlier intervention, confirm appropriate treatment choices, strengthen client communications, and inform check-up and monitoring schedules that are most appropriate for the patient.

The new Catalyst[®] SDMA Test can be stored in the freezer with current Catalyst[®] chemistry slides and can be run with other Catalyst chemistry slides in any slide order. By eliminating the reagent cup and moving the reagent onto the slide, workflow and efficiency have been improved. Improved workflow means that results can be available faster, giving back time to veterinary staff and increasing in-clinic proficiency and timely decision-making.

In conclusion, the new Catalyst SDMA Test maintains excellent performance and provides real-time results to support the veterinarian, patient, and client with the most complete set of clinical information for evaluating and managing kidney health.

References

- 1. Hall JA, Yerramilli M, Obare E, Yerramilli M, Yu S, Jewell DE. Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in healthy geriatric cats fed reduced protein foods enriched with fish oil, L-carnitine, and medium-chain triglycerides. *Vet J.* 2014;202(3):588–596. doi:10.1016/j.tvjl.2014.10.021
- 2. Hall JA, Yerramilli M, Obare E, Yerramilli M, Almes K, Jewell DE. Serum concentrations of symmetric dimethylarginine and creatinine in dogs with naturally occurring chronic kidney disease. J Vet Intern Med. 2016;30(3):794–802. doi:10.1111/jvim.13942
- Hall JA, Yerramilli M, Obare E, Li J, Yerramilli M, Jewell DE. Serum concentrations of symmetric dimethylarginine and creatinine in cats with kidney stones. PLoS One. 2017;12(4):e0174854. doi:10.1371/journal.pone.0174854
- 4. Nabity MB, Lees GE, Boggess MM, et al. Symmetric dimethylarginine assay validation, stability, and evaluation as a marker for the early detection of chronic kidney disease in dogs. J Vet Intern Med. 2015;29(4):1036–1044. doi:10.1111/jvim.12835
- 5. Braun JP, Lefebvre HP, Watson AD. Creatinine in the dog: a review. Vet Clin Pathol. 2003;32(4):162–179. doi:10.1111/j.1939-165x.2003.tb00332.x
- 6. Dahlem DP, Neiger R, Schweighauser A, et al. Plasma symmetric dimethylarginine concentration in dogs with acute kidney injury and chronic kidney disease. J Vet Intern Med. 2017;31(3):799–804. doi:10.1111/jvim.14694
- 7. Yerramilli M, Farace G, Quinn J, Yerramilli M. Kidney disease and the nexus of chronic kidney disease and acute kidney injury: the role of novel biomarkers as early and accurate diagnostics. *Vet Clin North Am Small Anim Pract*. 2016;46(6):961–993. doi:10.1016/j.cvsm.2016.06.011
- 8. CLSI. Measurement Procedure Comparison and Bias Estimation Using Patient Samples; Approved Guideline—Third Edition. CLSI document EP09-A3. Clinical and Laboratory Standards Institute; 2013.
- Ernst R, Ogeer J, McCrann D, et al. Comparative performance of IDEXX SDMA Test and the DLD SDMA ELISA for the measurement of SDMA in canine and feline serum. PLoS One. 2018;13(10):e0205030. doi:10.1371/journal.pone.0205030
- Mack RM, Hegarty E, McCrann DJ, Michael HT, Grauer GF. Longitudinal evaluation of symmetric dimethylarginine and concordance of kidney biomarkers in cats and dogs. Vet J. 2021;276:105732. doi:10.1016/j.tvjl.2021.105732
- 11. Michael HT, Mack RM, Hegarty E, McCrann DJ, Grauer GF. A longitudinal study of the persistence of increased creatinine and concordance between kidney biomarkers in cats and dogs. *Vet J.* 2021;276:105729. doi:10.1016/j.tvjl.2021.105729